Claudia Leporati

Claudia Leporati

Auto-generated profile, based on publicly available information

Claudia Leporati

Dermatology Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
CBCarlotta Bertolina
Carlotta Bertolina
MBMarinella Bertolotti
Marinella Bertolotti
CLClaudia Leporati
Claudia Leporati
AAAntonina Maria De Angelis
Antonina Maria De Angelis
SDSara Delfanti
Sara Delfanti
Federica GrossoFederica Grosso
Federica Grosso
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.